ID
5510
Description
EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan Inclusion Criteria: - Age greater than or equal to 18 years - Current hospitalization for chronic congestive heart failure with admission up to 48 hours prior to randomization. Chronic heart failure is defined as requiring treatment for a minimum of 30 days prior to hospitalization. The subject must have signs of extracellular volume expansion, defined as two or more of the following: a) jugular venous distention; b) pitting edema (>1+); or c) dyspnea. - NYHA Class III or IV at the time of hospitalization. - Left Ventricular Ejection Fraction <= 40% within one year Exclusion Criteria - Women who will not adhere to the reproductive precautions as outlined in the Informed Consent form - Positive urine pregnancy test - Inability to provide written informed consent - Cardiac surgery within 60 days of potential study enrollment, excluding percutaneous coronary interventions - Planned revascularization procedures, electrophysiologic (EP) device implantation, cardiac mechanical support implantation, cardiac transplantation, or other cardiac surgery within 30 days following study enrollment - Subjects who are on cardiac mechanical support - History of bi-ventricular pacer placement within the last 60 days - Co-morbid condition with an expected survival less than six months - Subjects with acute ST segment elevation myocardial infarction at the time of hospitalization - History of sustained ventricular tachycardia or ventricular fibrillation within 30 days, unless in the presence of an automatic implantable cardioverter defibrillator - History of a cerebrovascular accident within the last 30 days - Hemodynamically significant uncorrected primary cardiac valvular disease - Hypertrophic cardiomyopathy (obstructive or non-obstructive) - CHF due to uncorrected thyroid disease, active myocarditis or known amyloid cardiomyopathy - Subjects with progressive or episodic neurological disease such as multiple sclerosis or history of multiple strokes - History of primary significant liver disease or acute hepatic failure, as defined by the investigator - History of poorly controlled diabetes mellitus - Morbid obesity, defined as > 159 kg (or 350 lbs) or BMI > 40 - Supine systolic arterial blood pressure < 90 mmHg - Serum creatinine > 3.5 mg/dL or > 309.4 mmol/L - Serum potassium > 5.5 mEq/L or > 5.5 mmol/L - Hemoglobin < 9 g/dL or < 90 g/L - History of hypersensitivity and/or idiosyncratic reaction to benzazepine derivatives (such as benazapril) - History of drug or medication abuse within the past year, or current alcohol abuse - Inability to take oral medications - Participation in another clinical drug or device trial within the past 30 days - Previous participation in this or any other tolvaptan clinical trial
Keywords
Versions (3)
- 12/11/13 12/11/13 - Martin Dugas
- 8/7/14 8/7/14 - Martin Dugas
- 8/27/15 8/27/15 - Martin Dugas
Uploaded on
August 7, 2014
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility NCT00071331 Heart Failure
Similar models
Eligibility
- StudyEvent: Eligibility
102518004 (SNOMED CT 2010_0731)
439401001 (SNOMED CT 2010_0731)
195110006 (SNOMED CT 2010_0731)
I50.0 (ICD-10 Version 2009)
422008005 (SNOMED CT 2010_0731)
139248000 (SNOMED CT 2010_0731)
10054547 (MedDRA 13.1)
139201002 (SNOMED CT 2010_0731)
10013963 (MedDRA 13.1)
R06.0 (ICD-10-CM Version 2010)
E13368 (CTCAE Version 4.03)
420816009 (SNOMED CT 2010_0731)
70822001 (SNOMED CT 2010_0731)
10036586 (MedDRA 13.1)
57054005 (SNOMED CT 2010_0731)
10000891 (MedDRA 13.1)
I21 (ICD-10 Version 2009)
410 (ICD-9-CM Version 2011)
44103008 (SNOMED CT 2010_0731)
10047281 (MedDRA 13.1)
I47.2 (ICD-10 Version 2009)
I49.01 (ICD-10-CM Version 2010)
E10230 (CTCAE Version 4.03)
230690007 (SNOMED CT 2010_0731)
10042244 (MedDRA 13.1)
I63.9 (ICD-10-CM Version 2010)
E12826 (CTCAE Version 4.03)
233873004 (SNOMED CT 2010_0731)
10020871 (MedDRA 13.1)
LP18015-5 (LOINC Version 232)
10047890 (MedDRA 13.1)
107647005 (SNOMED CT 2010_0731)
LP35925-4 (LOINC Version 232)
10005894 (MedDRA 13.1)
140075008 (SNOMED CT 2010_0731)
386534000 (SNOMED CT 2010_0731)
10003146 (MedDRA 13.1)
45007003 (SNOMED CT 2010_0731)
I95 (ICD-10-CM Version 2010)
458 (ICD-9-CM Version 2011)
57302007 (SNOMED CT 2010_0731)
26416006 (SNOMED CT 2010_0731)
10013654 (MedDRA 13.1)
LP36310-8 (LOINC)
305.90 (ICD-9-CM Version 2011)
15167005 (SNOMED CT 2010_0731)
10001584 (MedDRA 13.1)
LP36309-0 (LOINC)
305.0 (ICD-9-CM Version 2011)
F10.1 (ICD-10-CM Version 2010)